Terminated PHASE3 INTERVENTIONAL 2-arm NCT03699956

RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer (REPLATINUM)

A Phase 3, Controlled, Open-label, Randomized Study of RRx-001 Administered Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond Small Cell Lung Cancer

Sponsor: EpicentRx, Inc.

Conditions Carcinoma, Small Cell Lung

Interventions Cisplatin/carboplatin plus etoposide RRx-001 + eLOOP Device

Updated 16 times since 2018 Last updated: Mar 22, 2024 Started: Dec 24, 2018 Primary completion: Aug 11, 2022 Completion: Mar 1, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

RRx-001 will be studied under a new global, phase 3 clinical trial

Other terminated trials from EpicentRx, Inc.

More terminations from EpicentRx, Inc.

Other Carcinoma, Small Cell Lung trials with similar outcome

Browse all Carcinoma, Small Cell Lung trials

Listed as NCT03699956, this PHASE3 trial focuses on Carcinoma, Small Cell Lung and remains terminated or withdrawn. Sponsored by EpicentRx, Inc., it has been updated 16 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

16 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Apr 2024 — Jul 2024 [monthly]

Terminated PHASE3
Nov 2022 — Apr 2024 [monthly]

Terminated PHASE3

Status: Active Not Recruiting → Terminated

▶ Show 11 earlier versions

Sep 2021 — Nov 2022 [monthly]

Active Not Recruiting PHASE3
Jan 2021 — Sep 2021 [monthly]

Active Not Recruiting PHASE3
Aug 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE3
May 2020 — Aug 2020 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Mar 2020 — May 2020 [monthly]

Recruiting PHASE3
Dec 2019 — Mar 2020 [monthly]

Recruiting PHASE3
Sep 2019 — Dec 2019 [monthly]

Recruiting PHASE3
Apr 2019 — Sep 2019 [monthly]

Recruiting PHASE3
Feb 2019 — Apr 2019 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Dec 2018 — Feb 2019 [monthly]

Not Yet Recruiting PHASE3
Nov 2018 — Dec 2018 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

EpicentRx, Inc.

Data source: EpicentRx, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Chicago, United States , Denver, United States , Houston, United States , Jackson, United States , Knoxville, United States , Lebanon, United States , Louisville, United States , Oklahoma City, United States , Omaha, United States and 8 more locations